* Bristol Myers Squibb - In May 2016, co sold the business comprising an alliance with Reckitt Benckiser Group including several OTC products sold primarily in Mexico and Brazil
BRIEF-Germany's Merck KGaA, AmoyDx collaborate to bring liquid biopsy RAS biomarker testing to China
* Merck and Amoy Diagnostics Co Ltd collaborate to bring liquid biopsy RAS biomarker testing to China
LONDON, July 28 U.S. and British health officials have created a new alliance with a budget of hundreds of millions of dollars to accelerate the development of new antibiotics and tackle the growing problem of drug resistance.
* Adaptimmune receives access to priority medicines (PRIME) regulatory support for its Spear T-cell therapy targeting NY-ESO for treatment of soft tissue sarcoma Source text for Eikon: Further company coverage:
July 28 Bristol-Myers Squibb Co reported disappointing second-quarter sales of its Yervoy melanoma treatment on Thursday, raising concerns about the long-term prospects for one of its most important cancer medicines and sending its shares lower.
No related earnings announcements are currently scheduled within the next 7 days.